Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
Recruiting
N/A
Interventional Study
Obesity
Body Composition
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 99
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Massachusetts General Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medication…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
1. Age ≥ 18 years old at time of signing informed consent
2. Started treatment with incretin therapy (liraglutide, semaglutide, tirzepatide, or retatrutide) within the past 2 months or planning to start this treatment
a. Potential participants switching GLP1-RA therapies due …
Contacts